Showing 15 posts of 15 posts found.


Astellas announces FDA approval for Izervay for GA treatment

August 7, 2023
Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …

Roche image

FDA clears Roche eye drug

February 9, 2015
Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab

The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …

France ‘to approve’ Avastin use

July 3, 2014
Sales and Marketing AMD, France, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The French government is planning to allow Roche’s cancer drug Avastin to be prescribed off-label to treat wet age-related macular …

set your sights image

Novartis launches Facebook ‘retina app’

October 15, 2013
Medical Communications AMD, Bayer, Lucentis, Novartis, set your sights

Novartis, the world’s biggest eye-care drugmaker, has launched a new Facebook retina app to raise awareness of retinal disease. The …

regeneron image

Sanofi ups stake in Regeneron

February 13, 2013
Sales and Marketing AMD, Regeneron, Sanofi, Zaltrap

Sanofi is increasing its stake in Regeneron Pharmaceuticals by buying shares on the open market and from existing shareholders. The …

Novartis image

Novartis eye drug nears approval

January 21, 2013
Sales and Marketing AMD, CHMP, Jetria, Novartis

Novartis’ eye drug Jetrea has been given a positive opinion by the CHMP, pushing it to the brink of approval. …

Microneedles image

Microneedles could transform delivery of drugs to the eye

July 24, 2012
Manufacturing and Production, Research and Development AMD, avastin, microneedles

Researchers in the US have demonstrated for the first time that drugs can be successfully delivered to the eye using …

Stem cell trial aims to cure macular degeneration

June 17, 2011
Research and Development AMD, Advanced Cell Technology, Stargardt’s Macular Dystrophy, Stem cells, stem cell

A groundbreaking trial to explore the use of stem cells to treat macular degeneration has been launched. US company Advanced …

Lucentis boosted by diabetic vision study

May 24, 2010
Research and Development, Sales and Marketing AMD, DME, Lucentis, Novartis

A phase III trial of Novartis’ ranibizumab has shown it to be superior at promoting vision gain in patients with …

Novartis and charity team up on AMD campaign

February 18, 2009
Medical Communications, Sales and Marketing AMD, ophthalmology

Novartis has teamed up with blindness charity the RNIB on a new campaign to promote awareness of age-related macular degeneration …

NICE bends to pressure over Lucentis

December 14, 2007
Sales and Marketing AMD, Lucentis, NICE

NICE is set to change its guidance for blindness treatment Lucentis following a barrage of complaints over its failure to …

NICE to re-think blindness drugs decision

August 9, 2007
Sales and Marketing AMD, Lucentis, Macugen, NICE

NICE will delay issuing final guidance on two blindness drugs after an unprecedented patient outcry over its decision to block …

NICE set to block blindness drugs

June 15, 2007
Sales and Marketing AMD, Lucentis, Macugen, NICE

Most patients in England and Wales will be denied access to drugs for the leading cause of sight loss if …

New blindness treatment moves closer to market

November 28, 2006
Sales and Marketing AMD, Lucentis, Novartis

Patients suffering from the leading cause of blindness could soon benefit from a new treatment after it gained preliminary approval …

New Novartis blindness treatment filed in Europe

March 2, 2006
Sales and Marketing AMD, Lucentis, Novartis

Lucentis, a new treatment for neovascular age-related macular degeneration or ‘wet AMD’ has been submitted by Novartis to the European …

Latest content